Abstract |
Elevated absolute monocyte counts (AMCs) have been reported to indicate poor prognosis for patients with lymphoproliferative disease, including those with follicular lymphoma (FL) receiving various treatments. We evaluated the prognostic impact of AMC in 150 consecutive FL patients who received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. Progression-free survival (PFS) did not differ significantly according to the AMC level. Univariate and multivariate analyses did not indicate a prognostic significance of AMC for PFS. Thus, the AMC is not a prognostic factor for FL patients treated with R-CHOP. However, immunochemotherapy might influence the prognostic impact of AMC.
|
Authors | Reina Watanabe, Naoto Tomita, Kumiko Kishimoto, Satoshi Koyama, Eriko Ogusa, Yoshimi Ishii, Kazuho Miyashita, Shiro Matsuura, Shin Fujisawa, Yukako Hattori, Hirotaka Takasaki, Atsuko Fujita, Rika Ohshima, Hideyuki Kuwabara, Chizuko Hashimoto, Katsumichi Fujimaki, Rika Sakai, Yoshiaki Ishigatsubo |
Journal | Leukemia research
(Leuk Res)
Vol. 37
Issue 10
Pg. 1208-12
(Oct 2013)
ISSN: 1873-5835 [Electronic] England |
PMID | 23927994
(Publication Type: Journal Article)
|
Copyright | Copyright © 2013 Elsevier Ltd. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal, Murine-Derived
- R-CHOP protocol
- Rituximab
- Vincristine
- Doxorubicin
- Cyclophosphamide
- Prednisone
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal, Murine-Derived
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cyclophosphamide
(therapeutic use)
- Doxorubicin
(therapeutic use)
- Female
- Humans
- Leukocyte Count
- Lymphoma, Follicular
(diagnosis, drug therapy, mortality)
- Male
- Middle Aged
- Monocytes
- Neoplasm Grading
- Neoplasm Staging
- Prednisone
(therapeutic use)
- Prognosis
- Retrospective Studies
- Rituximab
- Vincristine
(therapeutic use)
|